Norway’s health and life science research births a competitive industry with life-saving outcomes
Page date: published 12 June 2024; updated 26 August 2026; 6 min read (as rendered).
The article presents health and life science as one of Norway’s national export initiatives and describes strengths in biopharma, medical technology, digital health, oncology, ultrasound and imaging, radiopharmaceuticals, cell and gene therapy, diagnostics and precision medicine. It reports EUR 2–3 billion in sector exports, naming GE HealthCare, Bayer and Thermo Fisher among leading contributors. It also cites a government decision to invest EUR 6 billion in life-science infrastructure and a new Oslo university hospital; these figures and plans are article claims.
Oslo Science City is described as hosting 8,000 researchers, 40,000 students and 300 startups. Research examples include IMPRESS-Norway’s precision-cancer clinical trial, NorTrials, InPreD and CONNECT, a public-private cancer precision-medicine consortium. The page also names research hubs in Trondheim (NTNU, SINTEF and St. Olav’s), Bergen (Haukeland University Hospital and proton therapy), and Tromsø (UiT and the University Hospital of North Norway). Several facility opening dates in the article refer to 2024–2025 and are now historical; confirm current status.
The health-data section describes Biobank Norway and national registries, including the Cancer Registry (established 1951) and Cardiovascular Disease Registry. The article characterizes Norway’s universal health service, digitization, clean energy, water and collaborative work culture as foundations for research and commercial development. These are source-page claims; performance measures and investment details are not independently verified here.
Related link: Health and life science.